Table 1 Patient characteristics (n = 95)
Patient characteristics | Patients treated with anti-PD-1/PD-L1 therapy (n = 95), n (%) |
|---|---|
Age at initiation of anti-PD-1/PD-L1 therapy (years) | |
 Median | 62 |
 Range | 30–80 |
Sex | |
 Male | 66 (69.5) |
 Female | 29 (30.5) |
ECOG | |
 0 | 25 (26.3) |
 1 | 61 (64.2) |
 2 | 9 (9.5) |
Tumor type | |
 Lung cancer (NSCLC: n = 20, small cell lung cancer: n = 5) | 25 (26.3) |
 Esophageal carcinoma | 17 (17.9) |
 Liver cancer | 11 (11.6) |
 Head and neck cancer | 8 (8.4) |
 Genital system cancer | 6 (6.3) |
 Colorectal cancer | 7 (7.4) |
 Gastric carcinoma | 7 (7.4) |
 Urogenital carcinoma | 4 (4.2) |
 Cutaneous soft tissue carcinoma | 3 (3.2) |
 Melanoma | 2 (2.1) |
 Gallbladder carcinoma and bile duct carcinoma | 2 (2.1) |
 Others | 3 (3.2) |
TNM clinical classification | |
 III | 29 (30.5) |
 IV | 58 (61.1) |
 Unknown | 7 (7.4) |
Treatment lines at initiation of anti-PD-1/PD-L1 therapy | |
 First-line | 36 (37.9) |
 Second-line | 29 (30.5) |
 Third-line and above | 30 (31.6) |
Treatment | |
 Immunotherapy | 38 (40) |
 Immunotherapy + targeted therapy | 22 (23.2) |
 Immunotherapy + chemotherapy | 31 (32.6) |
 Immunotherapy + chemotherapy + targeted therapy | 4 (4.2) |
Baseline ACE | |
 Mean ± SD | 0.12 ± 0.017 |
Baseline PLR | |
 Mean ± SD | 204.899 ± 102.712 |
Baseline NLR | |
 Median | 3.381 |
 Range | 1.021–40.625 |